Premium
Ixekizumab as treatment of erythrodermic psoriasis
Author(s) -
Trovato Emanuele,
Orsini Corinne,
Russo Filomena,
Cortonesi Giulio,
Rubegni Pietro
Publication year - 2021
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.14868
Subject(s) - ixekizumab , medicine , acitretin , psoriasis , dermatology , methotrexate , interleukin 23 , interleukin 17 , secukinumab , immunology , cytokine , psoriatic arthritis
Erytrhodermic psoriasis (EP) is a rare subset of psoriasis that is considered a dermatologic emergency. Due to its limited clinical evidence, pathogenesis is largely unknown and its treatment represents a challenge. Conventional therapies such as methotrexate, cyclosporine, and acitretin are still considered first‐line of treatment but it is necessary to study the efficacy and safety of biologics, including antitumor necrosis factor (TNF), anti‐interleukin (IL)‐23, and anti‐IL17 agents to define new guidelines of treatment. Here, we report two cases of patients with EP treated with ixekizumab.